Evidence map›Paper›PMID 39554345›Full record

ReviewFood science & nutrition2024

Diosmin: A promising phytochemical for functional foods, nutraceuticals and cancer therapy.

Lubna Rahman, Ali Talha Khalil, Syed Ahsan Shahid, Zabta Khan Shinwari, Zainab M Almarhoon, Amnah Alalmaie, Javad Sharifi-Rad, Daniela Calina

Abstract readReview
In one paragraph

Review in Food science & nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Linking phytochemistry to bioactivity:Frontiers in chemistry · 2026
    Article
  6. Liver disorders and phytotherapy.Toxicology reports · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lubna RahmanDepartment of Biotechnology Quaid-i-Azam University Islamabad Pakistan.
Ali Talha KhalilDepartment of Pathology Lady Reading Hospital Medical Teaching Institution Peshawar Pakistan.
Syed Ahsan ShahidDepartment of Biotechnology Quaid-i-Azam University Islamabad Pakistan.
Zabta Khan ShinwariDepartment of Plant Sciences Quaid-i-Azam University Islamabad Pakistan.
Zainab M AlmarhoonDepartment of Chemistry College of Science, King Saud University Riyadh Saudi Arabia.
Amnah AlalmaieDepartment of Pharmaceutics College of Pharmacy, King Khalid University Abha Saudi Arabia.
Javad Sharifi-RadDepartment of Biomedical Sciences College of Medicine, Korea University Seoul Republic of Korea.ORCID https://orcid.org/0000-0002-7301-8151
Daniela CalinaDepartment of Clinical Pharmacy University of Medicine and Pharmacy of Craiova Craiova Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diosmin, a potent bioflavonoid derived from citrus fruits, has gained significant attention for its anticancer potential, reflecting a critical need in the ongoing battle against cancer. Amidst increasing cancer incidence, the quest for safer and more effective treatments has brought diosmin to the forefront, given its unique pharmacological profile distinct from other flavonoids. Diosmin's anticancer mechanisms are multifaceted, involving apoptosis induction, angiogenesis inhibition, and metastasis prevention. Extensive research encompassing cellular studies, animal models, and limited clinical trials underscores its efficacy not only against cancer but also in managing chronic venous insufficiency and hemorrhoids, attributing to its anti-inflammatory properties. Furthermore, diosmin exhibits low toxicity and complements conventional chemotherapy, proposing its utility as an adjunct therapy in cancer treatment protocols. The review delves into the specific anticancer advantages of diosmin, distinguishing it from the broader flavonoid category. It provides a detailed analysis of its implications in preclinical and clinical settings, advocating for its consideration in the oncological therapeutic arsenal. By juxtaposing diosmin with other herbal medicines, the review offers a nuanced perspective on its role within the wider context of natural anticancer agents, emphasizing the need for further clinical research to substantiate its efficacy and safety in oncology.

Indexed as

anticancer properties; apoptosischemotherapy adjunctdiosminflavonoidspharmacological applicationsphytochemicals

Identifiers

PMID39554345
PMCPMC11561841

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.